KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $1.0 billion.

  • Vir Biotechnology's Liabilities and Shareholders Equity fell 3196.19% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 billion, marking a year-over-year decrease of 2851.96%. This contributed to the annual value of $1.4 billion for FY2024, which is 2710.95% down from last year.
  • As of Q3 2025, Vir Biotechnology's Liabilities and Shareholders Equity stood at $1.0 billion, which was down 3196.19% from $1.2 billion recorded in Q2 2025.
  • Vir Biotechnology's 5-year Liabilities and Shareholders Equity high stood at $2.9 billion for Q1 2022, and its period low was $1.0 billion during Q3 2025.
  • Over the past 5 years, Vir Biotechnology's median Liabilities and Shareholders Equity value was $1.8 billion (recorded in 2024), while the average stood at $1.8 billion.
  • Per our database at Business Quant, Vir Biotechnology's Liabilities and Shareholders Equity skyrocketed by 15424.18% in 2022 and then plummeted by 3270.77% in 2024.
  • Vir Biotechnology's Liabilities and Shareholders Equity (Quarter) stood at $2.0 billion in 2021, then surged by 43.38% to $2.8 billion in 2022, then plummeted by 31.51% to $1.9 billion in 2023, then fell by 27.11% to $1.4 billion in 2024, then dropped by 27.12% to $1.0 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.0 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.3 billion for Q1 2025.